NMTC (n1mtc.com) צמיחת רווח למניה השנה

Patents and FDA approvals create significant barriers to entry for competitors in neurosurgery. The annual net income per share trend illustrates current financial trajectories, where -31.80 reflects the metric's baseline. NeuroOne Medical Technologies (NMTC) generates revenue through the sale of innovative electrodes for Parkinson's disease, while the integration of monitoring systems into clinics ensures steady demand for consumables.

For NeuroOne Medical Technologies (NMTC), a supplier of neuromonitoring electrodes, this indicator serves as a measure of monetization efficiency for high-precision diagnostic solutions. The metric calculates the percentage deviation of current net earnings per share from the same value last year. By analyzing year-over-year EPS dynamics, an investor can observe the smoothness of the business's profitability recovery. Growth in this figure confirms the scaling of sales across neurological centers, while a decline signals hidden operational risks.